XenoTherapeutics to Purchase Repare Therapeutics for $1.82 per Share Along with One Contingent Value Right
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Acquisition Announcement: Repare Therapeutics has entered into an agreement with XenoTherapeutics and Xeno Acquisition Corp. for Xeno to acquire all common shares of Repare.
Cash Payment Details: Shareholders are expected to receive a cash payment of approximately $1.82 per share at closing, based on Repare's cash balance after deducting transaction costs and liabilities.
Contingent Value Rights: Each shareholder will receive a non-transferable contingent value right for additional cash payments related to future receivables and net proceeds from existing partnerships and product licenses.
Closing Timeline: The transaction is anticipated to close in the first quarter of 2026.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
